UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Biochemical Society transactions, 2016-04, Vol.44 (2), p.412

2016

Volltextzugriff (PDF)

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages

Nature communications, 2020-12, Vol.11 (1), p.6298-16, Article 6298

2020

Volltextzugriff (PDF)

Racial disparities and referral for genetic counseling

Cancer, 2024-02, Vol.130 (4), p.505-506

Yeku, Oladapo O.

2024

Volltextzugriff (PDF)

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Frontiers in immunology, 2021-04, Vol.12, p.663379-663379

2021

Volltextzugriff (PDF)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Scientific reports, 2017-09, Vol.7 (1), p.10541, Article 10541

2017

Volltextzugriff (PDF)

Structural basis for antibody recognition of the proximal MUC16 ectodomain

Journal of ovarian research, 2024-02, Vol.17 (1), p.41-41, Article 41

2024

Volltextzugriff (PDF)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Nature biotechnology, 2018-10, Vol.36 (9), p.847-856

2018

Volltextzugriff (PDF)

CAR T Cells for Neuroblastoma

The New England journal of medicine, 2023-04, Vol.388 (14), p.1328-1331

2023

Volltextzugriff (PDF)

Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer

The New England journal of medicine, 2023-05, Vol.388 (18), p.1711-1714

2023

Volltextzugriff (PDF)

Intraperitoneal Therapy for Ovarian Cancer - Some Answers, More Questions, and Missed Opportunities

NEJM evidence, 2023-05, Vol.2 (5), p.EVIDe2300048

Yeku, Oladapo O

2023

Volltextzugriff (PDF)

Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure

The New England journal of medicine, 2021-05, Vol.384 (20), p.1943-1950

2021

Volltextzugriff (PDF)

High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options

Reproductive sciences (Thousand Oaks, Calif.), 2024-04

2024

Volltextzugriff (PDF)

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma

British journal of cancer, 2024-05, Vol.130 (9), p.1463-1476

2024

Volltextzugriff (PDF)

Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

Molecular cancer therapeutics, 2022-05, Vol.21 (5), p.775-785

2022

Volltextzugriff (PDF)

Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy

American journal of clinical oncology, 2022-01, Vol.45 (1), p.36

2022

Volltextzugriff (PDF)

Abstract 1836: Structural basis for recognition of MUC16 expressed in various cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1836-1836

2021

Volltextzugriff (PDF)

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5616-TPS5616

2023

Volltextzugriff (PDF)

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14597-e14597

2023

Volltextzugriff (PDF)

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5595-5595

2023

Volltextzugriff (PDF)

Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5571-5571

2023

Volltextzugriff (PDF)

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2523-2523

2023

Volltextzugriff (PDF)

Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.12-12

2018

Volltextzugriff (PDF)

Abstract IA21: MUC16-directed immunotherapy for ovarian cancer

Clinical cancer research, 2020-07, Vol.26 (13_Supplement), p.IA21-IA21

2020

Volltextzugriff (PDF)

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5628-TPS5628

2023

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(26)
NUS Single-Journal Subscriptions
(22)
Journals@Ovid Ovid Full Text
(18)
MEDLINE
(15)
Ingenta
(13)
IngentaConnect Journals
(12)
Nature Journals
(4)
Nexis Uni
(2)
SpringerLink Series
(2)
Springer journals
(2)
Wiley Blackwell Single Titles
(1)
Wiley Online Library Full Collection 2018
(1)
SAGE Journals
(1)

8 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages

Racial disparities and referral for genetic counseling

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

Structural basis for antibody recognition of the proximal MUC16 ectodomain

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

CAR T Cells for Neuroblastoma

Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer

Intraperitoneal Therapy for Ovarian Cancer - Some Answers, More Questions, and Missed Opportunities

Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure

High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents

Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy

Abstract 1836: Structural basis for recognition of MUC16 expressed in various cancers

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer

Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1)

Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer

Abstract IA21: MUC16-directed immunotherapy for ovarian cancer

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC)

Suchergebnisse filtern